NetworkNewsBreaks – Cellect Biotechnology (NASDAQ: APOP) Treats First Cancer Patient In Phase I/II Trial of ApoGraft™; Shares Surge
Cellect Biotechnology (NASDAQ: APOP) is trading 26% higher mid-morning following word the company has treated the first blood cancer patient in the recently initiated phase I/II trial of its stem cell technology ApoGraft™. The intent of the trial is to assess the Cellect ApoGraft™ process which is designed to prevent Graft-versus-Host Disease (GvHD), a common complication linked to stem cell transplant. Additionally, the company expects to release definitive and complete results of its trial on healthy volunteers before the end of the first quarter this year. “Enrolling our first cancer patient to be treated using our groundbreaking method is a…







